Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

Curr Hematol Malig Rep. 2017 Dec;12(6):510-512. doi: 10.1007/s11899-017-0425-7.
No abstract available

Keywords: BCL2; BPDCN; Bromodomain; IL3R, CD123; NFkB; Targeted therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Bortezomib / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Dendritic Cells / cytology
  • Dendritic Cells / metabolism
  • Hematologic Neoplasms / drug therapy
  • Hematologic Neoplasms / metabolism
  • Hematologic Neoplasms / pathology*
  • Humans
  • Interleukin-3 Receptor alpha Subunit / chemistry
  • Interleukin-3 Receptor alpha Subunit / genetics
  • Interleukin-3 Receptor alpha Subunit / metabolism*
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism
  • Proteins / antagonists & inhibitors
  • Proteins / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Recombinant Fusion Proteins / therapeutic use
  • Sulfonamides / therapeutic use

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Interleukin-3 Receptor alpha Subunit
  • NF-kappa B
  • Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Recombinant Fusion Proteins
  • Sulfonamides
  • bromodomain and extra-terminal domain protein, human
  • Bortezomib
  • tagraxofusp
  • venetoclax